LobbyingHalozyme Therapeutics lobbying by quarter
Halozyme Therapeutics HALO's latest lobbying report covers Q2 2026, at $80K. The four quarters Q3 2025–Q2 2026 total $270K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Halozyme TherapeuticsHALO
- Latest quarter
- $80K
- Q2 2026 · 1 reports
- Last 12 months
- $270K
- Last 4 quarters
- vs last quarter
- +14.3%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $0 | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $20K | 1 |
| Q3 2023 | $60K | 1 |
| Q4 2023 | $60K | 1 |
| Q1 2024 | $60K | 1 |
| Q2 2024 | $60K | 1 |
| Q3 2024 | $60K | 1 |
| Q4 2024 | $60K | 1 |
| Q1 2025 | $60K | 1 |
| Q2 2025 | $60K | 1 |
| Q3 2025 | $60K | 1 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $70K | 1 |
| Q2 2026 | $80K | 1 |
Policy issues the reports name
- Health issues10 reports
- Medicare and Medicaid7 reports
A report that names several issues counts once for each.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)13 reports
- Health & Human Services, Dept of (HHS)13 reports
- HOUSE OF REPRESENTATIVES13 reports
- SENATE13 reports
Firms it paid
| Firm | ||
|---|---|---|
| Forbes-Tate | $770K | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| BARRETT THORNHILL | Legislative Assistant, Sen. Mike Crapo (2003-2006); Legislative Assistant, Rep. Pat Toomey (2002-2003) | Q2 2023 |
| MICHAEL ALEXANDER WILLIAMS | Legislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Doug Jones (2019); Legislative Correspondent, Sen. Doug Jones (2018-2019) | Q2 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Forbes-Tate | $80K |
| 04/18for Q1 | Forbes-Tate | $70K |
| 01/18for Q4 2025 | Forbes-Tate | $60K |
| 25/10/18for Q3 2025 | Forbes-Tate | $60K |
| 25/07/18for Q2 2025 | Forbes-Tate | $60K |
| 25/04/15for Q1 2025 | Forbes-Tate | $60K |
| 25/01/17for Q4 2024 | Forbes-Tate | $60K |
| 24/10/17for Q3 2024 | Forbes-Tate | $60K |
| 24/07/12for Q2 2024 | Forbes-Tate | $60K |
| 24/04/14for Q1 2024 | Forbes-Tate | $60K |
| 24/01/16for Q4 2023 | Forbes-Tate | $60K |
| 23/10/17for Q3 2023 | Forbes-Tate | $60K |
| 23/07/16for Q2 2023 | Forbes-Tate | $20K |
| 23/04/17for Q1 2023 | Forbes-Tate | Under $5,000 |
| 23/01/15for Q4 2022 | Forbes-Tate | Under $5,000 |